生活習慣病ナーシング　10　糖尿病とメタボリックシンドローム3

出版社： メヂカルフレンド社
著者：
発行日： 2008-08-28
分野： 看護学  >  臨床/成人/老人
ISBN： 9784839214500
電子書籍版： 2008-08-28 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

3,960 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

3,960 円(税込)

購入する

商品紹介

わが国の医療対策の最重要課題である生活習慣病をもつ患者の看護に役立つことを念頭に置いたシリーズ企画。安全・安楽な看護、根拠をもった看護の実践ができるように情報を整理。予防に対する知識から最新の治療・看護に関する知見まで、臨床の今を反映した内容。施設内医療から在宅医療の支援まで、セルフケアに必要な知識・技術に関する情報を整理。

目次

  • 生活習慣病ナーシング　10　糖尿病とメタボリックシンドローム3

    ―目次―

    第１章　糖尿病と慢性合併症と動脈硬化症
    第２章　糖尿病細小血管症の成因・発症機序
    第３章　動脈硬化症の成因・発症機序
    第４章　動脈硬化症の内科的管理
    第５章　糖尿病合併症の治療と看護
    第６章　禁煙(卒煙)指導とアルコール対策
    第７章　患者の自立・社会復帰のためのチーム医療の展開
    第８章　糖尿病診療・看護のための社会システム
    第９章　糖尿病の大規模臨床試験

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

2 糖尿病細小血管症の成因・発症機序

P.32 掲載の参考文献
1) Goto Y, et al.:Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study. Biomedecine & Pharmacotherapy 49, (6):269-277, 1995.
 
2) Hotta N, et al.:Long-Term Clinical Effects of Epalrestat, an Aldose Reductase Inhibitor, on Diabetic Peripheral Neuropathy:The 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial. Diabetes Care, 29 (7):1538-1544, 2006.
PubMed
3) Bril V, et al.:Long-Term Effects of Ranirestat (AS-3201) on Peripheral Nerve Function in Patients With Diabetic Sensorimotor Polyneuropathy. Diabetes Care, 29 (1):68-72, 2006.
PubMed
4) Andrali S S, et al.:Glucose mediates the translocation of NeuroD1 by O-linked glycosylation. J. Biol. Chem, 282 (21):15589-15596, 2007.
PubMed
5) Andreozzi F, et al.:Activation of the Hexosamine Pathway Leads to Phosphorylation of Insulin Receptor Substrate-1 on Ser307 and Ser612 and Impairs the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Insulin Biosyntihetic Pathway in RIN Pancreatic [beta]-Cells. Endocrinology, 145 (6):2845-2857, 2004.
PubMed
6) Koya D, King GL:Protein kinase C activation and the development of diabetic complications. Diabetes, 47 (6):859-866, 1998.
PubMed
7) Rikitake Y, Liao JK:Rho-Kinase Mediates Hyperglycemia-Induced Plasminogen Activator Inhibitor-1 Expression in Vascular Endothelial Cells. Circulation, 111 (24):3261-3268, 2005.
PubMed
8) Quagliaro L, et al.:Intermittent high glucose enhances ICAM-1, VCAM-1 and E-selectin expression in human umbilical vein endothelial cells in culture:The distinct role of protein kinase C and mitochondrial superoxide production. Atherosclerosis, 183 (2):259-267, 2005.
 
9) Aiello LP, et al.:The Effect of Ruboxistaurin on Visual Loss in Patients With Moderately Severe to Very Severe Nonproliferative Diabetic Retinopathy:Initial Results of the Protein Kinase C [beta] Inhibitor Diabetic Retinopathy Study (PKC-DRS) Multicenter Randomized Clinical Trial. Diabetes, 54 (7):2188-2197, 2005.
 
10) Vinik A I, et al.:Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C [beta]-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial. Clinical Therapeutics, 27 (8):1164-1180, 2005.
PubMed
11) Tuttle K R, et al.:The Effect of Ruboxistaurin on Nephropathy in Type 2 Diabetes. Diabetes Care, 28:2686-2690, 2005.
PubMed
12) Baynes J W, Thorpe SR:Role of oxidative stress in diabetic complications:a new perspective on an old paradigm. Diabetes, 48 (1):1-9, 1999.
 
13) Huebschmann A G, et al:Diabetes and Advanced Glycoxidation End Products. Diabetes Care, 29 (6):1420-1432, 2006.
PubMed
14) Vasan S, et al:An agent cleaving glucose-derived protein crosslinks in vitro and in vivo Nature, 382:275-278, 1996.
PubMed
15) Brownlee M:The pathobiology of diabetic complications A unifying mechanism Diabetes 54:1615-1625, 2005.
PubMed
16) Nishikawa T, et al.:Normalizing mitochondrial superoxide production blocks three pathways of hyperglycemic damage Nature, 404:787-790, 2000.
PubMed
17) Inoguchi T, Nawata H:NAD (P) H oxidase activation:a potential mechanism for diabetic vascular complications, progressive beta-cell dysfunction and metabolic syndrome. Current Drug Targets, 6:495-501, 2005.
PubMed

4 動脈硬化の内科的管理

P.70 掲載の参考文献
1) Blacher J, et al.:Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients. Arch Intern Med, 160:1085-1089, 2000.
 
2) Benetos A, et al.:Pulse pressure:a predictor of long-term cardiovascular mortality in a French male population. Hypertension, 30:1410-1415, 1997.
 
3) Anderson KM, et al.:Cardiovascular disease risk profiles. Am Heart J, 121:293-298, 1991.
PubMed
4) Multiple risk factor intervention trial research group:Multiple risk factor intervention trial ; risk factor changes and mortality results. JAMA, 248:1465-1477, 1982.
 
5) Tanizaki Y et al.:Incidence and risk factors for subtypes of coerebral infarction in a general population ; the Hisayama study. Stroke, 31:2616-2622, 2000.
 
6) Chobanian AV, et al.:The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure:The JNC 7 report. JAMA, 289:2560-2572, 2003.
PubMed
7) Guidelines Subcommittee:1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens, 17:151-183, 1999.
PubMed
8) Burt VL, et al.:Prevalence of hypertension in the US adult population. Results from the third national health and nutrition examination survey, 1988-1991. Hypertension, 25:305-313, 1995.
PubMed
9) 日本高血圧学会高血圧治療ガイドライン作成委員会編:高血圧治療ガイドライン 2004, ライフサイエンス出版, 2004.
 
10) Tsuji I, et al.:Proposal of reference values for home blood pressure measurements:prognostic criteria based on a prospective observation of the general population in Ohasama, Japan. Am J Hypertens, 10:409-418, 1997.
PubMed
11) Pickering TG, et al.:Masked hypertension. Hypertension, 40:795-796, 2002.
PubMed
12) 本糖尿病学会編:糖尿病専門医研修ガイドブック, 診断と治療社, 2006, p.237-241.
 
13) American Diabetes association:Clinical Practice Recommendations 2007 Diabetes Care, 30 (1):15, 2007.
 
14) Hansson L, et al.:Effect of intensive blood-pressure lowering and acetylsalicylic acid in patients with hypertension:Principal results of the Hypertension Optimal treatment (HOT) randomized trial. Lancet, 351:1755-1762, 1998.
PubMed
15) United Kingdom Prospective Diabetes Study (UKPDS) Group:Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS38). BMJ, 317:703-713, 1998.
 
16) 日本糖尿病学会編:科学的根拠に基づく糖尿病診療ガイドライン, 改訂第2版,. 南江堂, 2007, p.157-170.
 
17) The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group:Major outcomes in high-risk hypertensive patients randomized to angiotensin converting enzyme inhibitor or calcium channel blocker vs diuretic:The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA, 288:2981-2997, 2002.
PubMed
18) Heart Outcomes Prevention Evaluation (HOPE) Study Investigations:Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus:Results of the HOPE study and MICRO-HOPE substudy. Lancet, 355:253-259, 2000.
PubMed
19) Lindholm LH, et al.:Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint in hypertension study (LIFE):A randomized trial against atenolol. Lancet,359:104-1010, 2002.
PubMed
20) Estacio RO, et al.:The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med, 338:645-652, 1998.
PubMed
21) Tatti P, et al.:Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care, 21:597-603, 1998.
PubMed
22) Julius S, et al.:Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine:The VALUE randomized trial. Lancet, 19:2022-2031, 2004.
 
23) Chaturvedi N, et al.:Effect of lisinopri on progression of retinopathy in normotensive people with type l diabetes.:The EUCLID Study Group:EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes mellitus. Lancet, 351:28-31, 1998.
 
24) Dahlof B, et al.:Prevention of cardiovascular events with an hypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA):a multicentre randomised controlled trial. Lancet, 366:895-906, 2005.
PubMed
25) 日本動脈硬化学会編:動脈硬化性疾患疾患予防ガイドライン, 2007年版, 日本動脈硬 化学会, 2007.
 
26) Kannel WB, et al.:Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. Ann Intern Med, 74:1-12, 1971.
PubMed
27) Greenland P, et al.:Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA, 290:891-897, 2003.
PubMed
28) 村勢敏郎:高脂血症診療ガイド, 文光堂, 2005.
 
29) Lefebvre P, et al.:Sorting out the roles of PPAR a in energy metabolism and vascular homeostasis. J Clin Invest, 116:571-580, 2006.
PubMed
30) Keech A et al.:Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study):randomized controlled trial. Lancet, 366:1849-1861, 2005.
 
31) Yokoyama, et al.:Effect of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia:rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS). Am Heart J, 146:613-620, 2003.
PubMed
32) Yokoyama et al.:Effect of eicosapentaenoic acid (EPA) on major coronary events in hypercholesterolemic patients:The Japan EPA Lipid Intervention Study (JELIS). Lancet, 369:1090-1098, 2007.
 
33) The Kyushu Lipid Intervention Study Group:A coronary primary intervention study of Japanese men:Study design, implementation and baseline data. J Atheroscler Thromb, 3:95-104, 1996.
 
34) The Kyushu Lipid Intervention Study Group:Pravastatin use and risk of coronary events and cerebral infarction in Japanese men with moderate hypercholesterolemia:The Kyushu Lipid Intervention Study. J Atheroscler Thromb, 7:110-121, 2000.
PubMed
35) Sasaki J, et al.:Reduction in serum total cholesterol and risks of coronary events and cerebral infarction in Japanese men-The Kyushu Lipid Intervention Study. Circ J, 67:473-478, 2003.
PubMed
36) Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study Group:Design and baseline characteristics of a study of primary prevention of coronary events with pravastatin among Japanese with mildly elevated cholesterol levels. Circ J, 68:860-867, 2004.
 
37) Nakamura H, et al. ; MEGA Study Group:Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study):a prospective randomized controlled trial. Lancet, 368:1155-1163, 2006.
 
38) Ito H, et al.:A comparison of low versus standard dose pravastatin therapy for the prevention of cardiovascular events in the elderly:The Pravastatin Anti-atherosclerotic Trial in the Elderly (PATE) . J Atheroscler Thromb, 8:33-44, 2001.
 
39) Ouchi Y, et al.:Influences of age, sex, and LDL-C changes on cardiovascular risk reduction with pravastatin treatment in elderly Japanese patients:A post hoc analysis of data from the Pravastatin Anti-atherosclerosis Trial in the Elderly (PATE). Curr Ther Res, 67:241-256, 2006.
PubMed
40) Matsuzaki M et al.:Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia-Primary prevention cohort study of the Japan lipid intervention trial (J-LIT). Circ J, 66:1087-1095, 2002.
 
41) Mabuchi H, et al.:Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia and coronary heart disease-Secondary prevention cohort study of the Japan lipid intervention trial (J-LIT). Circ J, 66:1096-1100, 2002.
 
42) Matsuzawa Y, et al.:Sustained reduction of serum cholesterol in low-dose 6-year simvastatin treatment with minimum side effects in 51,321 Japanese hypercholesterolemic patients-Implication of the J-LIT study, a large scale nationwide cohort study. Circ J, 67:287-294, 2003.
 
43) AbbottRD, et al.:The impact of diabetes on survival following myocardial infarction in men vs women:The Framingham Study. JAMA 260:3456-3460, 1988.
 
44) Kannel WB, McGee DL:Diabetes and cardiovascular diseases:The Framingham Study. JAMA, 241:2035-2038, 1979.
PubMed
45) Lerner DJ, Kannel WB:Patterns of coronary heart disease morbidity and mortality in the sexes:A 26-year follow-up of the Framingham population. Am Heart J, 111:383-390, 1986.
PubMed
46) Scheidt-Nave C, et al.:Resting electrocardiographic abnormalities suggestive of asymptomatic ischemic heart disease associated with non-insulin-dependent diabetes mellitus in a defined population. Circulation, 81:899-906, 1990.
 
47) Garcia MJ, et al.:Morbidity and mortality in diabetics in the Framingham population:Sixteen year follow-up study. Diabetes, 23:105-111, 1974.
PubMed
48) Stamler J, et al.:Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention trial. Diabetes Care, 16:434-444, 1993.
PubMed
49) Haffner SM, et al.:Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med, 339:229-234, 1998.
PubMed
50) Fujishima M, et al.:Diabetes and cardiovascular disease in a prospective population survey in Japan:the Hisayama study. Diabetes, 45 (3):14-16, 1996.
 
51) 日本糖尿病学会編:科学的根拠に基づく糖尿病診療ガイドライン, 改訂第2版, 南江堂, 2007, p.171-181.
 
52) Diabetes Atherosclerosis Intervention Study investigator:Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes:The Diabetes Atherosclerosis Intervention Study, a rondomised study. Lancet, 357:905-910, 2001.
 

5 糖尿病合併症の治療と看護

P.128 掲載の参考文献
1) 福田哲也編著:糖尿病ナーシング<Nursing mook12>, 学習研究社, 2002.
 
2) 河盛隆造総監修:合併症を未然に防ぐ糖尿病の治療とケア, 医学芸術社, 2004.
 
3) 池田匡監:代謝・内分泌疾患<Nursing Selection>, 学習研究社, 2002.
 
4) Remuzzi G, et al.:Nephropathy in Patients with Type 2 Diabetes. N Engl J Med, 346:1145, 2002.
PubMed
5) 日本糖尿病学会編:糖尿病専門医研修ガイドブック, 改定第2版, 診断と治療社, 2003.
 
6) 日本糖尿病学会編:科学的根拠に基づく糖尿病診療ガイドライン, 改訂第2版, 南江堂, 2007.
 
7) 糖尿病性腎症のすべて, 腎と透析, 51, 2001.
 
8) 高橋徳江:混乱させずに導ける食事指導が成功するパターン, エキスパートナース, 23 (9):58-59, 2007.
 
9) 小島操子:内分泌・代謝疾患患者の看護, 医学書院, 2002, p.157-160.
 
10) 葛谷英嗣編:糖尿病の治療と看護, 南江堂, 2003, p.190-197.
 
11) John B, et al.:Primary Prevention of Cardiovascular Diseases in People With Diabetes. A Scientific Statement From the American Heart Association and the American Diabetes Association. Circulation, 115:114-126, 2007.
 
12) Barret EJ, et al.:Consensus development conference on the diagnosis of coronary heart disease in people with diabetes. Diabetes Care, 21:1551-1559, 1998.
 
13) 日本循環器学会:虚血性心疾患の一次予防ガイドライン, 2006年改訂版. http://www.j-circ.or.jp/guideline/
 
14) 日本循環器学会:心筋梗塞の二次予防ガイドライン, 2006年改訂版. http://www.j-circ.or.jp/guideline/
 
15) 日本循環器学会:急性冠症候群の診療に関するガイドライン, 2002. http://www.j-circ.or.jp/guideline/
 
16) Heistad DD:Unstable Coronary-Artery Plaques. N Engl J Med, 349:2285, 2005.
 
17) Houston-Miller N. Smoking cessation. In:Houston-Miller N, Taylor CB, eds. Lifestyle Management for Patients with Coronary Heart Disease. Champaigne, IL. Human Kinetics, 85-104, 1995.
 
18) Evidenceに基づく日本人脳梗塞患者の医療ガイドライン策定に関する研究班編著:脳梗塞とはどんな病気?, 日本脳卒中協会, 2006.
 
19) 羽倉稜子編:ナースがおこなう糖尿病フットケア, 南江堂, 2006, p.2, 4, 51-59.
 
20) 日本糖尿病教育・看護学会編:糖尿病看護フットケア技術, 2005, p.10, 20, 50, 55.
 
21) 杉田和枝:糖尿病患者のフットケア, ナーシング . トゥデイ, 20 (8):24, 2005.
 
22) Loe H:Periodontal disease. The sixth complication of diabetes Mellitus. Diabetes Care, 16:329-334, 1993.
PubMed
23) Nishimura F, et al.:Negative effects of chronic inflammatory periodontal disease on diabetes mellitus. J Int Acad Periodontal, 2:49-55, 2000.
PubMed
24) Nelson RG, et al.:Periodontal disease and NIDDM in Pima Indians. Diabetes Care, 13:836-840, 1990.
PubMed
25) Stewart JE, et al.:The effect of periodontal treatment on glycemic control in patients with type 2 diabetes mellitus. J Clin Periodontol, 28 (4):306-10, 2001.
PubMed
26) Inoue M, et al.:Diabetes mellitus and the risk of cancer:results from a largescale population-based cohort study in Japan. Arch Intern Med, 166 (17):1871-1877, 2006.
PubMed

6 禁煙 (卒煙) 指導とアルコール対策

P.145 掲載の参考文献
1) The Osaka Health Survey, 岡田邦夫, 他:大阪健康研究, 第42回糖尿病学会年次学術集会, 1995.
 
2) Morrish JJ, et al.:Risk factors for macrovascular disease in diabetes mellitus:the London follow up to WHO multinational study of vascular disease in diabetics. Diabetologia, 34:590-594, 1991.
 
3) Stamler J, et al.:Diabates, other risk factors, and 12-yr cardiovascular mortality for men screened in multiple risk factor intervention trial. Diabates Care, 16:434-444, 1994.
 
4) Forelholm R, Nurros K:Cigarette smoking and risk of primary intracerebral haemorrhage. A population-based case-sontrol study. Acta Neural Scand, 87:367-370, 1993.
 
5) 井村裕夫, 他:喫煙の糖・脂質代謝並びに動脈硬化発症に及ぼす影響, 平成2年 度喫煙科学研究財団研究年報, p.340-344.
 
6) Klein R, et al.:Is cigarette smoking associated with diabetic retinopathy?Am J Epidemiol, 118:228-238, 1983.
PubMed
7) Morgado P B, et al.:The acute effect of smoking on retinal blood flow in subjects with and without diabetes. ophthalmology, 101:1220-1226, 1994.
PubMed
8) 日本呼吸器学会:禁煙宣言. http://www.jrs.or.jp/index.html
 
9) Prochaska JO, et al.:Standardized, individualized, interactive, and personalized self-help programs for smoking cessation. Health Psychol, 12:399-405, 1993.
PubMed
10) 香川靖雄, 他:人体の構造と機能及び疾病の成り立ち各論I <健康・栄養科学シリーズ>, 南江堂, 2005, p.220.
 
11) 日本糖尿病学会編:科学的根拠に基づく糖尿病診断ガイドライン, 改訂第2版, 南江堂, 2007, p.27-28.
 
12) 加藤眞三, 他:生活習慣病の予防と治療, 臨床スポーツ医学, 臨時増刊号, 19:310-313, 2002.
 
13) 大屋純子, 他:エネルギー源としてのアルコールの意義と栄養指導上の注意点, 臨床栄養, 109 (1):51-55, 2006.
Medical*Online

7 患者の自立・社会復帰のためのチーム医療の展開

P.180 掲載の参考文献
1) 日本糖尿病療養指導士認定機構編:日本糖尿病療養指導士受験ガイドブック2004, メディカルレビュー社.
 
2) 日本糖尿病療養指導士認定機構編:日本糖尿病療養指導士受験ガイドブック2002, メディカルレビュー社.
 
3) 吉岡成人編:糖尿病療養指導士のための糖尿病外来ケア・チェックシート, 医学書院, 2006.
 
4) 山田信博監:糖尿病療養指導士のための虚血性心疾患合併防止の生活指導書, ヴァンメディカル, 2006.
 
5) 日本糖尿病学会編:糖尿病治療ガイド, 2004, 文光堂.
 
6) 平成18年度版看護白書, 日本看護協会出版会, 2006. p.20.
 
7) 近藤雅巳:メタボリックシンドローム対策総合戦略事業 (モデル) 事業の取り組みから ; モデル事業に取り組んで, 保健師ジャーナル, 63 (6):99, 2007.
 
8) メタボリックシンドローム ; 疾患概念から食事療法まで, 臨床栄養, 108 (6), 2006.
 
9) 日本糖尿病療養指導士受験ガイドブック2004 ; 糖尿病療養指導士の学習目標と課題, メディカルレビュー社, 2004.
 
10) 福田哲也編:糖尿病ナーシング, 学習研究社, 2002.
 
11) 安酸史子編著:糖尿病合併症ナーシング ; 患者さんの気持ちに寄り添うアプローチ, 医歯薬出版, 2005.
 
12) 松原まどか, 藤田芳邦:看護に役立つ! 人体の神秘の世界へご招待 ; からだと病気とミクロのはなし, 看護学雑誌, 71 (4):338-341, 2007.
 
13) 宮崎美砂子:メタボリックシンドローム対策総合戦略事業 (モデル) 事業の取り組みから, 保健師ジャーナル, 63 (6):492-499, 2007.
 

9 糖尿病の大規模臨床試験

P.231 掲載の参考文献
1) The Diabetes Control and Complications Trial Research Group:The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The New England Journal of Medicine, 329:977-986, 1993.
 
2) The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group:Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The New England Journal of Medicine, 342:381-389, 2000.
 
3) Nathan DM, et al.:Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type l diabetes. The New England Journal of Medicine, 353:2643-2653, 2005.
 
4) UK Prospective Diabetes Study (UKPDS) Group:Intensive blood-glucose control With sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) . Lancet 352:837-853, 1998.
 
5) UK Prospective Diabetes Study (UKPDS) Group:Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet, 352:854-865, 1998.
PubMed
6) UK Prospective Diabetes Study (UKPDS) Group:Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ, 317:703-713, 1998.
PubMed
7) Stratton IM, et al.:Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35):prospective observational study. BMJ, 321:405-412, 2000.
PubMed
8) Adler AI, et al.:Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36):prospective observational study. BMJ, 321:412-419, 2000.
PubMed
9) Ohkubo Y, et al.:Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus:a randomized prospective 6-year study. Diabetes Res Clin Pract, 28:103-117, 1995.
PubMed
10) 厚生労働省:今後の中長期的な厚生労働科学研究の在り方に関する専門委員会中間報告書概要. http://www.mhlw.go.jp/shingi/2005/04/dl/s0421-4b.pdf
 
11) 厚生労働省:戦略研究の創設にかかる検討状況 (報告). http://www.mhlw.go.jp/shingi/2005/03/s0318-8h.html
 
12) Tuomilehto J, et al.:Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med, 344:1343-1350, 2001.
PubMed
13) Knowler WC, et al.:Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med, 346:393-403, 2002.
 
14) Kosaka K et al.:Prevention of type 2 diabetes by lifestyle intervention:a Japanese trial in IGT males. Diabetes Res Clin Pract, 67:152-162, 2005.
PubMed
15) 葛谷英嗣, 他:日本糖尿病予防研究 (Japan Diabetes Prevention Program ; JDPP) の経過報告, Diabetes Journal, 33:126-129, 2005.
 
16) 足立淑子, 山津幸司:肥満に対するコンピュータを用いた健康行動変容プログラム, 肥満研究, 10:31-36, 2004.
 
17) 山口幸生, 他:行動変谷技法を活用した非対面式身体活動促進プログラムの有効性, 明治生命厚生事業団第15回健康医科学研究助成論文集, 15, 155-165, 2000.
 
18) Gaede P, et al.:Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med, 348:383-393, 2003.
PubMed
19) Dormandy JA, et al.:Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):a randomised controlled trial. Lancet, 366:1279-1289, 2005.
PubMed
20) Khaw KT, et al.:Association of hemoglobin A with cardiovascular disease and mortality in adults:the European prospective investigation into cancer in Norfolk. Ann Intern Med, 141:413-420, 2004.
PubMed
21) Lewington S, et al.:Age-specific relevance of usual blood pressure to vascular mortality:a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet, 360:1903-1913, 2002.
PubMed
22) Sever PS, et al.:Reduction in cardiovascular events with atorvastatin in 2532 patients with type 2 diabetes:Anglo-Scandinavian Cardiac Outcomes Trial-lipid-lowering arm (ASCOT-LLA). Diabetes Care, 28:1151-1157, 2005.
 
23) Colhoun HM, et al.:Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS):multicentre randomised placebo-controlled trial. Lancet, 364:685-696, 2004 (1-13).
 

書評

最近チェックした商品履歴

Loading...